Ascendis Pharma (ASND) director Bienaimé buys 400 Ordinary Shares

Rhea-AI Filing Summary

Ascendis Pharma A/S director Jean Jacques Bienaimé reported open-market purchases of the company’s Ordinary Shares. On May 26, 2026, he bought a total of 400 shares in two transactions, at weighted average prices of $236.235 and $239.3675 per share, executed across multiple trades within narrow intraday price ranges.

Insider Trade Summary

Net Buyer: 400 shares ($95,121)

Net Buy 2 txns

Insider BIENAIME JEAN JACQUES

Role null

Bought 400 shs ($95K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	200	$236.235	$47K
Purchase	Ordinary Shares	200	$239.3675	$48K

Holdings After Transaction: Ordinary Shares — 200 shares (Direct, null)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $235.93 to $236.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $239.245 to $239.490 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 400 shares Weighted average price 1: $236.235 per share Weighted average price 2: $239.3675 per share +2 more

5 metrics

Shares purchased 400 shares Total Ordinary Shares bought on May 26, 2026

Weighted average price 1 $236.235 per share First 200-share open-market purchase

Weighted average price 2 $239.3675 per share Second 200-share open-market purchase

Buy transactions 2 transactions Open-market purchases coded P, non-derivative

Net buy direction 400 shares net-buy No sells, gifts, or tax withholdings reported

Key Terms

open-market purchase, weighted average price, Ordinary Shares, Form 4

4 terms

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP

(City) (State) (Zip)

DENMARK

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/26/2026		P		200	A	$236.235(1)	200	D
Ordinary Shares	05/26/2026		P		200	A	$239.3675(2)	400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $235.93 to $236.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $239.245 to $239.490 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Michael Wolff Jensen as attorney-infact for Jean J Bienaime	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ascendis Pharma (ASND) report in this Form 4?

The filing shows director Jean Jacques Bienaimé made open-market purchases of Ascendis Pharma Ordinary Shares. He bought a total of 400 shares in two separate transactions on May 26, 2026, at weighted average prices around the mid-$230s.

How many Ascendis Pharma (ASND) shares did Jean Jacques Bienaimé buy?

Jean Jacques Bienaimé purchased 400 Ordinary Shares of Ascendis Pharma A/S. These were executed as two 200-share open-market transactions on May 26, 2026, as disclosed in the Form 4 insider filing data.

At what prices were the Ascendis Pharma (ASND) shares purchased in this Form 4?

The purchases were reported at weighted average prices of $236.235 and $239.3675 per share. Footnotes explain each price reflects multiple trades within narrow ranges around $236 and $239, respectively, on May 26, 2026.

What type of transaction did Ascendis Pharma (ASND) director BIENAIME JEAN JACQUES execute?

The director executed open-market purchases of Ordinary Shares, coded as P transactions. The Form 4 classifies these as non-derivative buys, with direct ownership reported and no related option exercises or derivative activity disclosed.

Does the Ascendis Pharma (ASND) Form 4 show any share sales or derivative exercises?

No share sales or derivative exercises are reported. The transaction summary shows two buy transactions, 400 shares bought, and zero sells, exercises, gifts, or tax-withholding events, indicating a net-buy position change in Ordinary Shares.

What do the weighted average price footnotes mean in the Ascendis Pharma (ASND) Form 4?

The footnotes clarify that each reported price is a weighted average across multiple trades. Actual trades occurred within specified ranges, and the reporting person offers to provide detailed trade-by-trade pricing information to the issuer, shareholders, or regulators upon request.